These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10974014)

  • 21. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.
    Moller DE; Greene DA
    Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854
    [No Abstract]   [Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor agonists.
    Willson TM; Wahli W
    Curr Opin Chem Biol; 1997 Aug; 1(2):235-41. PubMed ID: 9667857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.
    Miller AR; Etgen GJ
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1489-500. PubMed ID: 12943493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PPARs 2001: it's not over 'til the fat lady sings. 4-10 February 2001.
    Forman BM
    Trends Mol Med; 2001 Aug; 7(8):331-2. PubMed ID: 11516973
    [No Abstract]   [Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases.
    Oates JC; Reilly CM; Crosby MB; Gilkeson GS
    Arthritis Rheum; 2002 Mar; 46(3):598-605. PubMed ID: 11920394
    [No Abstract]   [Full Text] [Related]  

  • 26. Imaging and peroxisome proliferator-activated receptor agonists: uncovering their role in atherosclerosis development.
    Nissen SE
    Clin Cardiol; 2004 Jul; 27(7 Suppl 4):IV17-20. PubMed ID: 15470907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor-alpha and the pleiotropic responses to peroxisome proliferators.
    Tugwood JD; Aldridge TC; Lambe KG; Macdonald N; Woodyatt NJ
    Arch Toxicol Suppl; 1998; 20():377-86. PubMed ID: 9442309
    [No Abstract]   [Full Text] [Related]  

  • 28. Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands.
    Leibowitz SB; Kantoff PW
    Semin Oncol; 2003 Oct; 30(5):698-708. PubMed ID: 14571417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor alpha.
    Nomura M; Tanase T; Miyachi H
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2101-4. PubMed ID: 12127513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approach to microvascular angina (syndrome X).
    Seery JP
    J Am Coll Cardiol; 1995 May; 25(6):1472-3. PubMed ID: 7794362
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid metabolism: inflammatory-immune responses in atherosclerosis.
    Davidson J; Rotondo D
    Curr Opin Lipidol; 2003 Jun; 14(3):337-9. PubMed ID: 12840665
    [No Abstract]   [Full Text] [Related]  

  • 32. [Insulin resistance and arteriosclerosis].
    Yamada N
    Nihon Naika Gakkai Zasshi; 2001 Sep; 90(9):1748-52. PubMed ID: 11681055
    [No Abstract]   [Full Text] [Related]  

  • 33. Orphans await a real purpose in life.
    Tugwood JD
    Hum Exp Toxicol; 1996 Apr; 15(4):363-4. PubMed ID: 8845229
    [No Abstract]   [Full Text] [Related]  

  • 34. Fatty fish supplementation and risk of prostate cancer.
    Inoue K; Takano H; Yoshikawa T
    Lancet; 2001 Oct; 358(9290):1367. PubMed ID: 11684247
    [No Abstract]   [Full Text] [Related]  

  • 35. Pro-inflammatory mechanisms of a non-steroidal anti-inflammatory drug.
    Wood IC
    Trends Pharmacol Sci; 2002 Mar; 23(3):109. PubMed ID: 11879673
    [No Abstract]   [Full Text] [Related]  

  • 36. PPARs--second international symposium. From basic science to clinical applications. 19-22 March 2003, Florence, Italy.
    Gomaraschi M
    IDrugs; 2003 May; 6(5):429-31. PubMed ID: 12841204
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment and prognosis of syndrome X].
    Furukawa Y
    Nihon Rinsho; 1994 Aug; 52 Suppl(Pt 2):435-7. PubMed ID: 12440008
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors.
    Pan R; Liu J; Chen Y
    Front Pharmacol; 2023; 14():1144918. PubMed ID: 37435495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells.
    Chow YL; Sogame M; Sato F
    Sci Rep; 2016 Dec; 6():38129. PubMed ID: 27917887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of miR-378a in Metabolism, Angiogenesis, and Muscle Biology.
    Krist B; Florczyk U; Pietraszek-Gremplewicz K; Józkowicz A; Dulak J
    Int J Endocrinol; 2015; 2015():281756. PubMed ID: 26839547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.